- Home
- BIIB vs NTAP Comparison
BIIB vs NTAP Comparison
Compare BIIB & NTAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- NTAP
- Stock Information
- Founded
- BIIB 1978
- NTAP 1992
- Country
- BIIB United States
- NTAP United States
- Employees
- BIIB N/A
- NTAP N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- NTAP Electronic Components
- Sector
- BIIB Health Care
- NTAP Technology
- Exchange
- BIIB Nasdaq
- NTAP Nasdaq
- Market Cap
- BIIB 25.1B
- NTAP 24.9B
- IPO Year
- BIIB 1991
- NTAP 1995
- Fundamental
- Price
- BIIB $159.26
- NTAP $128.79
- Analyst Decision
- BIIB Buy
- NTAP Buy
- Analyst Count
- BIIB 25
- NTAP 19
- Target Price
- BIIB $258.57
- NTAP $135.94
- AVG Volume (30 Days)
- BIIB 1.6M
- NTAP 2.2M
- Earning Date
- BIIB 10-30-2024
- NTAP 11-21-2024
- Dividend Yield
- BIIB N/A
- NTAP 1.61%
- EPS Growth
- BIIB 10.05
- NTAP 69.33
- EPS
- BIIB 11.06
- NTAP 5.44
- Revenue
- BIIB $9,607,500,000.00
- NTAP $6,473,000,000.00
- Revenue This Year
- BIIB N/A
- NTAP $8.10
- Revenue Next Year
- BIIB N/A
- NTAP $5.45
- P/E Ratio
- BIIB $14.41
- NTAP $23.69
- Revenue Growth
- BIIB N/A
- NTAP 6.10
- 52 Week Low
- BIIB $153.62
- NTAP $83.62
- 52 Week High
- BIIB $268.30
- NTAP $135.45
- Technical
- Relative Strength Index (RSI)
- BIIB 35.47
- NTAP 59.50
- Support Level
- BIIB $158.44
- NTAP $121.91
- Resistance Level
- BIIB $165.29
- NTAP $129.96
- Average True Range (ATR)
- BIIB 3.42
- NTAP 4.01
- MACD
- BIIB 1.04
- NTAP 0.65
- Stochastic Oscillator
- BIIB 44.34
- NTAP 64.52
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About NTAP NetApp Inc.
NetApp Inc is a provider of enterprise data management and storage solutions. The company's segments include Hybrid Cloud and Public Cloud. It generates maximum revenue from the Hybrid Cloud segment. The Hybrid Cloud segment offers a portfolio of storage management and infrastructure solutions that help customers recast their traditional data centers with the power of cloud. This portfolio is designed to operate with public clouds to unlock the potential of hybrid, multi-cloud operations. Hybrid Cloud is composed of software, hardware, and related support, as well as professional and other services.